Pediatrix Medical Group, Inc. is a physician-led healthcare organization that provides clinical services for newborns, mothers, and children. The company operates a national network of affiliated physicians who staff and manage neonatal intensive care units (NICUs), maternal-fetal medicine practices, and other pediatric subspecialty units within hospitals. Its core services include neonatal care for premature or medically complex infants, maternal-fetal medicine for high-risk pregnancies, pediatric intensive care, pediatric hospitalist services, and pediatric surgery. Pediatrix also operates a newborn hearing screening program and offers virtual care solutions. The company partners with hospitals and health systems across the United States to deliver specialized care, while also conducting clinical research and providing continuing medical education. Incorporated in 1979 as Pediatrix Medical Group, Inc., the entity was later reorganized and is currently known as Pediatrix Medical Group, Inc.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Care Facilities Homepage pediatrix.com
Sector Healthcare IR page pediatrix.com/about/investors
Tags
neonatology, maternal-fetal medicine, pediatric intensive care, pediatric hospitalists, pediatric surgery, newborn hearing screening, hospital staffing, clinical research, virtual care, Pediatrix, Obstetrix, NEO Conference, Center for Research Education Quality and Safety
Press page pediatrix.com/about/for-media/news

Metrics

Valuation  
Market cap $ 2.009B
Market cap (USD) $ 2.009B
P/E 13.98
PEG 0.39
P/BV 2.36
P/S 1.03
P/OCF 8.86
P/FCF 7.95
Dividend yield —
Turnover / mcap —
Returns  
ROE 20.3%
ROI 11.3%
ROIC 10.9%
Profit margin 8.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 35.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 68.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.914B 2.013B 1.995B 1.972B 1.911B 1.734B 3.514B 3.647B — — — — — — — — — — — — — — — — — —
Net profit 165.388M -99.069M -60.408M 66.335M 130.964M -796.488M -1.498B 268.629M 320.372M 324.914M 336.32M 317.281M 280.517M 240.907M 217.997M 202.691M 175.804M 169.201M 142.722M 124.465M 89.037M 98.279M 84.328M 68.776M 30.428M 10.986M
Free cash flow 252.633M 184.551M 103.997M 137.233M 44.488M — — — — — — — — — — — 226.427M 165.711M 180.013M 164.398M 154.533M 116.696M 102.76M 89.849M 83.248M 31.803M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 21.39 13.12 9.3 14.86 27.21 24.54 27.79 33 53.44 66.66 71.66 66.11 53.38 79.52 72 67.27 60.68 31.69 — — — — — — — —
Price performance 12m 0.63 0.41 -0.37 -0.45 0.11 -0.12 -0.16 -0.38 -0.2 -0.07 0.08 0.24 -0.33 0.1 0.07 0.11 0.92 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 495M 504M 542M 499M 242M 302M 297M 272M 260M 230M
↳ YoY growth +11.4% +1.8% +7.6% -8.0% -51.5% +24.7% -1.7% -8.2% -4.5% -11.7%
↳ 5y CAGR +16.5% +15.2% +13.7% +7.2% -11.5% -9.4% -10.0% -12.9% -12.2% -1.0%
Borrowings, current (USD) 20M 1.4M 253,000 — — 2.49M 14.9M 14.9M 20.5M 26.8M
Borrowings, non-current (USD) 1.68B — — — — — 632M 618M 597M 571M
Lease liabilities (USD) — — 253,000 90.5M 71M 75.3M 76.9M 77.6M 50M 40.7M
Cash and deposits (USD) 55.7M 60.2M 36.7M 113M 1.12B 387M 9.82M 73.3M 230M 375M
Intangible assets (USD) 669M 640M 588M 274M 26.6M 21.6M 18.5M 21.2M 11.6M 16.9M
Right-of-use assets (USD) — — 0.00 82.8M 44.9M 51.3M 55.8M 61.7M 34.1M 31.1M
Net debt (borrowings + leases - cash) (USD) 1.65B -58.8M -36.5M — — -324M 82M 638M 438M 263M
Cash flow detail
Operating cash flow (USD) 444M 511M 290M 347M 205M 76.7M 167M 137M 207M 271M
Change in receivables (cash effect) (USD) -34M 7.8M -36.6M 7.85M 37.9M -72.7M -5.54M 26.3M 10.3M 30.6M
Change in payables (cash effect) (USD) 11.6M 24.6M 15.4M 104M 47.9M 21.3M 420,000 -11.9M 51.1M 28.3M
Share buybacks (cash effect) (USD) -61.8M -70.2M -302M -145M -8.49M -4.72M -88.5M -919,000 -1.7M -86.7M
Interest paid (cash effect) (USD) -60.5M -73.8M -82.5M -95.4M -110M -86.5M -116M -42.3M -40M -34.4M
Income taxes paid (cash effect) (USD) -176M -75.4M -185M -86.3M 27.8M -54.7M -26.9M -30.8M -4.67M -1.72M
Share-based compensation (USD) 34M 29.6M 38.7M 35.4M 39M 19M 16.1M 12.3M 11.9M 18M
Operating cash flow before change in receivables (USD) 478M 504M 327M 339M 167M 149M 172M 111M 196M 241M
Income detail
Total comprehensive income (USD) — — — — -793M 129M 61.3M -58.9M -97.9M 167M
Comprehensive income to owners (USD) — — — — -793M 129M 61.3M -58.9M -97.9M 167M
Reported Feb 10, 2017 Feb 14, 2018 May 2, 2019 Feb 20, 2020 Feb 17, 2023 Feb 17, 2023 Aug 3, 2023 Feb 20, 2024 Feb 20, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FORT LAUDERDALE, Fla., October 29, 2026 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.59 per share for the three months ended September 30, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.72.

For the 2026 third quarter, Pediatrix reported the following results:

•Net revenue of $501 million;

•Net income of $47 million; and

•Adjusted EBITDA of $85 million.

“We are pleased with our results this quarter, driven by both volume and pricing performing ahead of our expectations,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. “We continue to push operating efficiency paired with sector leading care quality, while considering high-value opportunities in adjacent businesses, as they arise.”

Operating Results– Three Months Ended September 30, 2026

Pediatrix’s net revenue for the three months ended September 30, 2026 was $501.4 million, compared to $492.9 million for the prior-year period.

In the News

Halloween’s Biggest Danger for Kids: What Parents Need to Know

Parade

October 11, 2026

Halloween should be fun, but safety should come first – especially when trick-or-treating with children. “Halloween is such a fun holiday to celebrate with kids, but it’s always important to consider safety so your family can fully enjoy the holiday, as accidents and choking may be fatal. We all want our kids to be healthy and safe,” said Makayla Romboy, M.D., a pediatric emergency medicine physician at Pediatrix® Emergency Medicine of Nevada. As a mother of two, Dr. Romboy never allows her children to dart into the street or cross mid-block, where drivers may not see them, while trick-or-treating. “The biggest safety threat to families on Halloween is cars,” said Dr. Romboy. She cited research showing that pedestrian fatalities are 43% higher on Halloween. “Drivers may be distracted by the festivities and have a hard time seeing kids in the dark,” explained Dr. Romboy. “Kids are also more likely to excitedly cross the street when trick-or-treating.”

View the full article on Parade

Tags:

Accent Waves Background

Advanced medical solutions. Care when and where it's needed.

Prenatal Care

Support for women’s health, pregnancy and high-risk care

Read More

Neonatal Care

Highly specialized care for newborn babies

Read More

Pediatric Specialty Care

Specialty and critical care for children

Read More

Virtual Care

Expanding access to care

Read More

© 2026 Pediatrix Medical Group. All Rights Reserved.

1301 Concord Terrace, Sunrise, FL 33323

In the News

Over-the-Counter Medicines During Pregnancy: What to Know

The Bump

October 6, 2026

During pregnancy, some commonly used medicines are off-limits, while others should be used only as a last resort. Although proton pump inhibitors (PPIs) are generally considered safe during pregnancy, providers often recommend them as a last resort, said Tania Lopez, CNM, a certified nurse-midwife at Pediatrix® OB Hospitalists of Texas. It’s best to try dietary changes, calcium carbonate antacids (such as Tums) or H2 blockers before a PPI, since more is known about their safety. According to Lopez, anti-diarrheals like Imodium are safe to use in pregnancy for a short period of time. Call your provider if diarrhea lasts more than two days, symptoms are severe or you have more than 8 to 10 episodes in a day, she said. Your provider may want to monitor you and help you rehydrate.

View the full article on The Bump

Tags:

Accent Waves Background

Advanced medical solutions. Care when and where it's needed.

Prenatal Care

Support for women’s health, pregnancy and high-risk care

Read More

Neonatal Care

Highly specialized care for newborn babies

Read More

Pediatric Specialty Care

Specialty and critical care for children

Read More

Virtual Care

Expanding access to care

Read More

© 2026 Pediatrix Medical Group. All Rights Reserved.

1301 Concord Terrace, Sunrise, FL 33323

Prompts

Pediatrix Medical Group, Inc. (ticker MD), listed in United States.

Company History

Date Change Detail
Aug 4, 2022 Renamed MEDNAX, INC. → PEDIATRIX MEDICAL GROUP, INC.
Jan 2, 2009 Renamed PEDIATRIX MEDICAL GROUP INC → MEDNAX, INC.
Jan 2, 2009 Renamed MEDNAX, INC. → PEDIATRIX MEDICAL GROUP INC

ETFs Holding Pediatrix Medical Group, Inc.

ETF Weight in ETF Shares Market value As of
RSMC 1.90% 436,458 $ 13.919M Nov 17, 2026
ECML 1.78% 68,566 $ 2.13M Nov 18, 2026
ASCE 1.71% 79,434 $ 2.012M Jun 30, 2026
BSMC 1.61% 105,504 $ 2.672M Jun 30, 2026
SIXS 1.35% 62,315 $ 1.957M Nov 12, 2026
EHLS 1.13% 19,130 $ 610.056K Nov 17, 2026
MYLD 1.05% 13,434 $ 356.135K Jul 31, 2026
VAMO 0.97% 39,567 $ 1.049M Jul 31, 2026
DSMC 0.63% 32,056 $ 811.978K Jun 30, 2026
BSVO 0.58% 444,453 $ 13.84M Nov 18, 2026
LITL 0.56% 1,033 $ 32.157K Nov 17, 2026
SYZ 0.48% 13,031 $ 330.075K Jun 30, 2026
AFSM 0.45% 20,392 $ 650.301K Nov 16, 2026
SMIZ 0.42% 43,542 $ 1.142M Aug 31, 2026
IVSS 0.34% 3,641 $ 92.227K Jun 30, 2026
SQLV 0.33% 3,707 $ 93.898K Jun 30, 2026
AVSC 0.19% 190,306 $ 6.069M Nov 16, 2026
SEIS 0.15% 34,450 $ 872.619K Jun 30, 2026
VFMF 0.13% 47,078 $ 1.235M Aug 31, 2026
DFAT 0.11% 1,145,839 $ 35.979M Nov 12, 2026
DFSV 0.10% 842,108 $ 26.442M Nov 12, 2026
RESM 0.10% 138 $ 3,495.54 Jun 30, 2026
SMDX 0.08% 3,269 $ 104.248K Nov 17, 2026
PSC 0.08% 72,885 $ 1.846M Jun 30, 2026
VFQY 0.06% 12,035 $ 315.678K Aug 31, 2026
DFAS 0.06% 625,808 $ 19.65M Nov 12, 2026
VFMO 0.05% 39,639 $ 1.04M Aug 31, 2026
JSTC 0.04% 3,570 $ 113.847K Nov 17, 2026
EBI 0.03% 8,887 $ 233.106K Aug 31, 2026
DXUV 0.02% 46,715 $ 1.467M Nov 12, 2026
DFSU 0.02% 12,472 $ 391.621K Nov 12, 2026
DFAC 0.01% 369,547 $ 11.604M Nov 12, 2026
MSSM 0.01% 2,075 $ 54.427K Aug 31, 2026
DCOR 0.01% 102,218 $ 3.21M Nov 12, 2026
DFAU 0.01% 23,765 $ 746.221K Nov 12, 2026
DFUS 0.00% 24,747 $ 777.056K Nov 12, 2026
DFUV 0.00% 1,602 $ 50.303K Nov 12, 2026